Pfizer cleared the next hurdle in the race to get its Covid-19 vaccine approved for emergency use in the U.S. after the Food and Drug Administration on Tuesday released documents that did not raise any new issues about its safety or efficacy.<br /><br />The analysis, conducted by FDA staff, affirmed that the coronavirus vaccine, developed by Pfizer and its German partner BioNTech, was 95% effective in preventing Covid-19 after two doses.
